Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

CNS compounds from ADIR that selectively bind to D4 receptors

July 16, 1998

Phase II clinical trial begins for fibromyalgia treatment

July 16, 1998

Risperidone: satellite symposia discuss impact on cognition and behavior

July 16, 1998

Pfizer reports pharmacokinetics of a novel anxiolytic agent - CP-93393

July 16, 1998

M-100907 improves positive and negative symptoms and is well tolerated in schizophrenics

July 15, 1998

Preliminary evidence of antidepressant effect for igmesine, a sigma ligand

July 15, 1998

Mitsui Toatsu describes potent, long-acting and orally bioavailable antipsychotic agents

July 15, 1998

CR-2945, a promising new anxiolytic agent in preclinical testing

July 15, 1998

World's first brain cell transplant performed in stroke patient

July 15, 1998

Centrally acting muscarinic agents discovered at American Home Products

July 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...